ACE抑制剂应与血管紧张素受体拮抗剂合用吗？
Should ACE Inhibitors be Combined with Angiotensin II Receptor Antagonists?
包括：激素受体和血管紧张素受体在瞳孔肌肉组织中起什么作用；
Among them: what effect do the hormone receptors and angiotensin receptors play in pupillary musculature;
血管紧张素受体阻滞药应作为卒中一级和二级预防的一线用药吗？
Should angiotensin receptor blockers be regarded as first-line drugs for stroke prevention in both primary and secondary prevention Settings?
我们评价了卒中后早期应用血管紧张素受体拮抗剂，替米沙坦，的作用。
We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.
对于该患者人群，这种血管紧张素受体拮抗剂还发挥了前所未有的血压控制作用。
The angiotensin receptor blocker also yielded unprecedented blood pressure control for this population of patients.
前言：目的：观察血管紧张素受体拮抗剂缬沙坦对肾病综合征大鼠的干预保护作用。
Objective: to observe the role of Angiotensin II receptor antagonist valsartan on kidney of rat with nephrotic syndrome.
血管紧张素转化酶抑制剂和血管紧张素受体拮抗剂联合用药治疗CKD是否比单药应用要好？
Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination therapy Better Than Monotherapy and Safe in Patients With CKD?
这些结果表明阿里克伦在减轻高血压合并左室肥厚患者心脏终末损伤方面，与血管紧张素受体阻滞剂的效果类似。
These findings suggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.
目的探讨血管紧张素受体拮抗剂缬沙坦对链脲佐菌素诱导的糖尿病大鼠糖代谢、氧化应激及胰腺病理结构的影响。
Objective to assess the effects of valsartan (an angiotensin receptor blocker, ARB) on glucose metabolism, oxidative stress and pancreatic pathology in streptozotocin-induced diabetic rats.
目前，我认为血管紧张素受体阻断剂是耐受更好的肾素-血管紧张素系统阻滞剂，因此我会在联合策略中包括这种药物。
I think at the moment, the angiotensin receptor blockers are the better tolerated blockers of the renin-angiotensin system, so I would include those in a combination.
目的研究血管紧张素转换酶抑制剂(acei)和血管紧张素受体拮抗剂(arb)对2型糖尿病肾病患者肾功能的保护作用。
Objective to investigate the protective effect of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor antagonist (ARB) on renal function of type 2 diabetic nephropathy patients.
我们研究了使用血管紧张素受体阻断剂（ARB）进行治疗是否能延缓或预防尿白蛋白正常的2型糖尿病患者出现微量蛋白尿。
We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria.
我们比较了血管紧张素转换酶抑制剂雷米普利、血管紧张素受体拮抗剂替米沙坦以及两药联合对有血管性疾病或高位糖尿病患者的作用。
We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.
也包括正在服用影响肾灌注或肾功能药物的患者，此类药物如利尿剂、ACE抑制剂、血管紧张素受体抑制剂(ARBs)、或许nsaids。
It also includes patients taking drugs that affect renal perfusion or function such as diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs) and possibly NSAIDS.
虽然小剂量的血管紧张素II注射对雄性小鼠血压没有影响，但却能显著减低雌鼠的平均动脉压，而此现象能够被血管紧张素受体拮抗剂PD123319所阻断。
Although this low dose had no effect on MAP in the male, it significantly decreased MAP in the female, and this effect was prevented by coinfusing the animals with PD123319, an antagonist of the AT2R.
去年，研究SARS病毒的医生发现该病毒与肾素血管紧张素系统的受体结合，他们起初感到不解，这是一条先前未与肺有关的途径。
Last year, doctors studying the SARS virus were at first confused to find that the virus bound to a receptor in the renin-angiotensin system, a pathway not previously associated with the lungs.
但是，对轻中度收缩性HF患者，螺内酯联合血管紧张素ii受体拮抗剂对左室(LV)逆重构的价值目前还不清楚。
However, the value of combining spironolactone with an angiotensin II receptor blocker on LV reverse remodeling in mild-to-moderate systolic HF is unclear.
依据上述论点，本研究利用AT2受体基因敲出小鼠，观察了AT2受体缺失后是否造成肾素-血管紧张素系统其它成分代偿性紊乱。
In the present study, we investigated whether gene deletion of AT2 receptor causes the compensatory chaos of renin-angiotensin system in mice.
抗高血压新药非肽类血管紧张素ii受体拮抗剂自二十世纪八十年代发现以来就受到了广泛的关注。
Antihypertensive non-peptide angiotensin II receptor antagonists have been paid much attention since it was found in 1980's.
受体阻滞剂（BB）和血管紧张素转换酶抑制剂（ACEI）的实际使用率分别为49·4%、65·4%。
The actual utilization rate of beta blockers(BB)and angiotensin-converting enzyme inhibitors(ACEI)was 49.4 and 65.4, respectively.
结果钙拮抗剂、肾上腺素受体阻滞药、血管紧张素转化酶抑制剂(acei)在用药金额、用药频度上分别占前三位。
Results the amount used DDDs of calcium antagonists, adrenergic receptor blockers and ACEI drugs were the head of three.
结果钙拮抗剂、肾上腺素受体阻滞药、血管紧张素转化酶抑制剂(acei)在用药金额、用药频度上分别占前三位。
Results the amount used DDDs of calcium antagonists, adrenergic receptor blockers and ACEI drugs were the head of three.
应用推荐